Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
December 18, 2019updated 19 Dec 2019 12:06pm

Overview of triple-negative breast cancer clinical trials

TNBC is a form of breast cancer that is not stimulated by estrogen, progesterone or the HER2 protein.

By GlobalData Healthcare

GlobalData analysed the number of clinical trials examining triple-negative breast cancer (TNBC) with start dates between 1 January 2009 and 11 December 2019.

TNBC is a form of breast cancer that is not stimulated by estrogen, progesterone or the HER2 protein.

Approximately 10–20% of breast cancers are triple-negative, as they fail to test for estrogen receptors, progesterone receptors or excess HER2 protein. Typically, TNBC fails to respond to normal hormonal therapy. However, other immunotherapies can be used to treat the condition.

Figure 1 shows the TNBC trials that GlobalData analysed by phase. The majority of TNBC trials were in Phase II (59%), followed by Phase I (26.0%), Phase III (9%), and Phase IV (3 %).

Figure 2 shows the top five countries that are conducting TNBC trials. The US had the most trials with 79.5%, whereas Spain had 6.9%, France had 5.7%, Germany had 4.1%, and Italy had 3.8%. Most of these trials were led by non-industry sponsors (57.9%).

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU